MX2022014312A - Inhibidores de sarcomero cardiaco. - Google Patents
Inhibidores de sarcomero cardiaco.Info
- Publication number
- MX2022014312A MX2022014312A MX2022014312A MX2022014312A MX2022014312A MX 2022014312 A MX2022014312 A MX 2022014312A MX 2022014312 A MX2022014312 A MX 2022014312A MX 2022014312 A MX2022014312 A MX 2022014312A MX 2022014312 A MX2022014312 A MX 2022014312A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- sub
- dihydrobenzofuran
- inden
- analogs
- Prior art date
Links
- 230000000747 cardiac effect Effects 0.000 title abstract 2
- 210000002235 sarcomere Anatomy 0.000 title abstract 2
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 title 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical class C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 208000019622 heart disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se proporcionan compuestos de fórmula (I): (ver Fórmula) Fórmula (I) o una sal farmacéuticamente aceptable de este, en donde A, Z, B, R1, R2, R3 G1, G2 y G3 son como se define en la presente. También se proporciona una composición farmacéuticamente aceptable que comprende un compuesto de fórmula (I) o una sal farmacéuticamente aceptable de este. También se proporcionan métodos para utilizar un compuesto de fórmula (I), o una sal farmacéuticamente aceptable de este.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862619643P | 2018-01-19 | 2018-01-19 | |
| US201862745724P | 2018-10-15 | 2018-10-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022014312A true MX2022014312A (es) | 2022-12-07 |
Family
ID=65324663
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020007532A MX2020007532A (es) | 2018-01-19 | 2019-01-18 | Inhibidores de sarcomero cardiaco. |
| MX2022014312A MX2022014312A (es) | 2018-01-19 | 2020-07-14 | Inhibidores de sarcomero cardiaco. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020007532A MX2020007532A (es) | 2018-01-19 | 2019-01-18 | Inhibidores de sarcomero cardiaco. |
Country Status (33)
| Country | Link |
|---|---|
| US (4) | US10836755B2 (es) |
| EP (2) | EP3740481B9 (es) |
| JP (3) | JP7401439B2 (es) |
| KR (1) | KR102797441B1 (es) |
| CN (3) | CN117924208A (es) |
| AU (2) | AU2019208331C1 (es) |
| BR (1) | BR112020014428A2 (es) |
| CA (1) | CA3252332A1 (es) |
| CL (2) | CL2020001871A1 (es) |
| CO (1) | CO2020009225A2 (es) |
| DK (1) | DK3740481T5 (es) |
| EC (1) | ECSP20044709A (es) |
| ES (1) | ES2986630T3 (es) |
| FI (1) | FI3740481T3 (es) |
| HR (1) | HRP20241014T2 (es) |
| HU (1) | HUE067913T2 (es) |
| IL (1) | IL276094B2 (es) |
| LT (1) | LT3740481T (es) |
| MA (1) | MA51620B1 (es) |
| MD (1) | MD3740481T3 (es) |
| MX (2) | MX2020007532A (es) |
| MY (1) | MY203855A (es) |
| NZ (1) | NZ765795A (es) |
| PH (1) | PH12020551090A1 (es) |
| PL (1) | PL3740481T3 (es) |
| PT (1) | PT3740481T (es) |
| RS (1) | RS66042B9 (es) |
| SG (1) | SG11202006296YA (es) |
| SI (1) | SI3740481T1 (es) |
| SM (1) | SMT202400329T1 (es) |
| TW (2) | TWI898447B (es) |
| UY (1) | UY38057A (es) |
| WO (1) | WO2019144041A1 (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020014428A2 (pt) | 2018-01-19 | 2020-12-01 | Cytokinetics, Inc. | composto, composição farmacêutica, e, métodos para o tratamento de uma doença cardíaca em um indivíduo, para o tratamento de uma doença ou condição que está associada com cavidade ventricular esquerda pequena e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia do miocárdio ou fibrose cardíaca, para o tratamento de uma doença ou condição selecionada dentre distrofias musculares e doenças de armazenamento do glicogênio e para inibição do sarcômero cardíaco |
| JP7610985B2 (ja) * | 2018-06-26 | 2025-01-09 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| EP3814342B1 (en) * | 2018-06-26 | 2022-07-27 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| CN112867539B (zh) | 2018-08-31 | 2024-08-06 | 赛特凯恩蒂克公司 | 心脏肌小节抑制剂 |
| EP4446314A3 (en) * | 2019-05-03 | 2025-03-12 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
| PL3999180T3 (pl) * | 2019-07-17 | 2024-09-23 | Cytokinetics, Inc. | Polimorfy (r)-n-(5-(5-etylo-1,2,4-oksadiazol-3-ilo)-2,3-dihydro-1h-inden-1-ylo)-1-metylo-1h-pirazolo-4-karboksyamidu |
| KR20220082803A (ko) * | 2019-07-17 | 2022-06-17 | 싸이토키네틱스, 인코포레이티드 | (r)-n-(5-(5-이소프로필-1,2,4-옥사디아졸-3-일)-2,3-디하이드로-1h-인덴-1-일)-2-메틸-2h-테트라졸-5-카르복사미드의 다형체들 |
| EP3999038B1 (en) * | 2019-07-17 | 2024-01-10 | Cytokinetics, Inc. | Cardiac sarcomere inhibitor oral formulations |
| JP2023540485A (ja) | 2020-08-28 | 2023-09-25 | マイオカーディア，インク | ミオシンモジュレーターによる治療方法 |
| CN112094253B (zh) * | 2020-09-10 | 2023-01-10 | 株式会社大熊制药 | 用于制备sglt抑制剂中间体的合成方法 |
| AU2022229390A1 (en) | 2021-03-04 | 2023-09-21 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| HRP20250174T1 (hr) | 2021-07-16 | 2025-04-11 | Cytokinetics, Inc. | Režimi za doziranje aficamtena za liječenje opstruktivne hipertrofične kardiomiopatije |
| JP2024530111A (ja) | 2021-08-03 | 2024-08-16 | サイトキネティックス， インコーポレイテッド | アフィカムテンを調製するための工程 |
| CA3249509A1 (en) | 2022-04-26 | 2023-11-02 | MyoKardia, Inc. | METHOD OF ADMINISTRATION OF MYOSIN INHIBITORS |
| TW202423423A (zh) | 2022-07-20 | 2024-06-16 | 美商胞質動力學公司 | 治療非阻塞性肥厚性心肌病之方法 |
| CA3262959A1 (en) | 2022-08-04 | 2024-02-08 | Cytokinetics, Incorporated | TREATMENT METHODS FOR OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY |
| WO2024040190A1 (en) | 2022-08-18 | 2024-02-22 | Cytokinetics, Incorporated | Indane and coumaran derivatives as fast skeletal muscle myosin inhibitors |
| WO2024134498A1 (en) | 2022-12-22 | 2024-06-27 | Assia Chemical Industries Ltd. | Solid state forms of aficamten and process for preparation thereof |
| CN115894361A (zh) * | 2022-12-28 | 2023-04-04 | 上海合全药业股份有限公司 | 一种钯催化合成1-乙酰基-6-氰基-四氢喹啉的方法 |
| WO2024179422A1 (zh) * | 2023-03-02 | 2024-09-06 | 苏州科睿思制药有限公司 | Aficamten的共晶及其制备方法和用途 |
| WO2025096779A2 (en) | 2023-11-01 | 2025-05-08 | Bristol Myers Squibb Company | Methods of treatment with a myosin inhibitor using protein levels |
| WO2025175141A1 (en) * | 2024-02-16 | 2025-08-21 | Cytokinetics, Incorporated | Fast skeletal muscle myosin inhibitors |
| WO2025198687A1 (en) | 2024-03-20 | 2025-09-25 | Cytokinetics, Incorporated | Methods for treating heart diseases |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US633499A (en) | 1899-06-29 | 1899-09-19 | Oil Well Supply Co | Coupling for pipes, tubes, or casings. |
| ATE372966T1 (de) | 1994-03-25 | 2007-09-15 | Isotechnika Inc | Verbesserung der effektivität von arzneimitteln duren deuterierung |
| US6334997B1 (en) * | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US5919785A (en) | 1996-04-03 | 1999-07-06 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| EP1503986B1 (en) | 2001-12-21 | 2015-09-30 | Cytokinetics, Inc. | Compositions and methods for treating heart failure |
| AU2002365057A1 (en) | 2001-12-21 | 2003-07-30 | Cytokinetics, Inc. | Compositions and methods for treating heart failure |
| US6855822B2 (en) * | 2002-06-24 | 2005-02-15 | Vivoquest, Inc. | Benzo[b]furan dimers |
| AU2004206860B2 (en) * | 2003-01-14 | 2010-03-18 | Cytokinetics, Inc. | Compounds, compositions and methods |
| WO2004064760A2 (en) | 2003-01-21 | 2004-08-05 | Archemix Corp. | Aptamer therapeutics useful in ocular pharmacotherapy |
| ATE524452T1 (de) | 2003-03-27 | 2011-09-15 | Cytokinetics Inc | Sulfonamide zur behandlung von kongestivem herzversagen, deren zusammensetzungen und verwendungen. |
| RU2006101541A (ru) | 2003-06-20 | 2006-06-10 | Амген Инк. (US) | Производные пиперазина и способ их применения |
| NZ552404A (en) | 2004-06-17 | 2010-04-30 | Cytokinetics Inc | Compounds, compositions and methods |
| US20060173183A1 (en) | 2004-12-31 | 2006-08-03 | Alantos Pharmaceuticals, Inc., | Multicyclic bis-amide MMP inhibitors |
| CN101137414A (zh) * | 2004-12-31 | 2008-03-05 | 欧兰拓制药股份有限公司 | 多环双酰胺mmp抑制剂 |
| CA2604916A1 (en) | 2005-04-22 | 2006-11-02 | Wyeth | Dihydrobenzofuran derivatives and uses thereof |
| WO2006128184A2 (en) * | 2005-05-20 | 2006-11-30 | Alantos-Pharmaceuticals, Inc. | Pyrimidine or triazine fused bicyclic metalloprotease inhibitors |
| WO2007078815A2 (en) | 2005-12-16 | 2007-07-12 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| RU2318818C1 (ru) | 2006-04-12 | 2008-03-10 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты) |
| SA08290245B1 (ar) | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم |
| US20090192168A1 (en) | 2008-01-04 | 2009-07-30 | Alex Muci | Compounds, Compositions and Methods |
| US20110275673A1 (en) | 2008-09-19 | 2011-11-10 | Yibin Xiang | Inhibitors of sphingosine kinase 1 |
| CN102803217B (zh) | 2009-05-15 | 2015-06-17 | 诺华股份有限公司 | 作为醛固酮合酶抑制剂的芳基吡啶 |
| US8592426B2 (en) | 2011-01-24 | 2013-11-26 | Hoffmann—La Roche Inc. | Aryl-benzocycloalkyl amide derivatives |
| US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| EP2760830B1 (en) * | 2011-09-27 | 2016-08-03 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
| KR102033190B1 (ko) | 2012-01-20 | 2019-10-16 | 이도르시아 파마슈티컬스 리미티드 | Ｐ２ｘ７ 수용체 길항제로서의 헤테로시클릭 아미드 유도체 |
| WO2014205234A1 (en) | 2013-06-21 | 2014-12-24 | MyoKardia, Inc. | Cycloalkyl-substituted pyrimidinedione compounds |
| SMT202000071T1 (it) | 2013-06-21 | 2020-03-13 | Myokardia Inc | Composti di pirimidinadione contro le condizioni cardiache |
| DK3080103T3 (en) | 2013-12-11 | 2018-07-30 | Biogen Ma Inc | BIARYL COMPOUNDS USED FOR TREATING HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY |
| WO2015142001A2 (ko) | 2014-03-21 | 2015-09-24 | 충남대학교산학협력단 | 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물 |
| US9663516B2 (en) | 2014-12-18 | 2017-05-30 | MyoKardia, Inc. | Bicyclic-pyrimidinedione compounds |
| MX2017009445A (es) * | 2015-01-20 | 2017-11-08 | Merck Sharp & Dohme | Inhibidores del factor xia. |
| MX385960B (es) | 2015-01-22 | 2025-03-18 | Myokardia Inc | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd). |
| CN105884752B (zh) * | 2015-02-13 | 2018-08-31 | 山东轩竹医药科技有限公司 | 并环类回旋酶和拓扑异构酶iv抑制剂 |
| WO2017055469A1 (en) | 2015-10-02 | 2017-04-06 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
| US20180368410A1 (en) | 2015-12-17 | 2018-12-27 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
| BR112018012378B1 (pt) | 2015-12-18 | 2022-12-20 | Syngenta Participations Ag | Composto da fórmula (i) e seu uso, composição agroquímica e método de controle ou prevenção de infestação de plantas úteis por microrganismos fitopatogênicos |
| EP3448519A4 (en) | 2016-04-29 | 2020-01-22 | Board Of Regents, The University Of Texas System | SIGMA RECEPTOR BINDING |
| WO2017222951A1 (en) | 2016-06-23 | 2017-12-28 | Merck Sharp & Dohme Corp. | 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors |
| CA3037537C (en) | 2016-09-27 | 2021-06-15 | Merck Sharp & Dohme Corp. | Chromane, isochromane and dihydroisobenzofuran derivatives as mglur2-negative allosteric modulators, compositions, and their use |
| WO2018089433A1 (en) | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PHENYL mTORC INHIBITORS AND USES THEREOF |
| JP2020023442A (ja) | 2016-12-19 | 2020-02-13 | 住友化学株式会社 | オキサジアゾール化合物及び植物病害防除方法 |
| WO2018156883A1 (en) | 2017-02-23 | 2018-08-30 | Board Of Regents, The University Of Texas System | Methods of treatment for cancer, sterol homeostasis, and neurological diseases |
| US10981900B2 (en) | 2017-02-28 | 2021-04-20 | Medshine Discovery Inc. | Spiro compound and use thereof |
| SMT202500413T1 (it) | 2017-08-04 | 2025-11-10 | Myokardia Inc | Mavacamten per l’uso nel trattamento di cardiomiopatia ipertrofica |
| BR112020014428A2 (pt) | 2018-01-19 | 2020-12-01 | Cytokinetics, Inc. | composto, composição farmacêutica, e, métodos para o tratamento de uma doença cardíaca em um indivíduo, para o tratamento de uma doença ou condição que está associada com cavidade ventricular esquerda pequena e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia do miocárdio ou fibrose cardíaca, para o tratamento de uma doença ou condição selecionada dentre distrofias musculares e doenças de armazenamento do glicogênio e para inibição do sarcômero cardíaco |
| SMT202200134T1 (it) | 2018-03-08 | 2022-05-12 | Incyte Corp | Composti di amminopirazindiolo come inibitori di pi3k-y |
| US10710994B2 (en) | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
| JP7610985B2 (ja) | 2018-06-26 | 2025-01-09 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| EP3814342B1 (en) | 2018-06-26 | 2022-07-27 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| CN112867539B (zh) | 2018-08-31 | 2024-08-06 | 赛特凯恩蒂克公司 | 心脏肌小节抑制剂 |
| US10981905B2 (en) | 2018-08-31 | 2021-04-20 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents |
| EP3999038B1 (en) | 2019-07-17 | 2024-01-10 | Cytokinetics, Inc. | Cardiac sarcomere inhibitor oral formulations |
| PL3999180T3 (pl) | 2019-07-17 | 2024-09-23 | Cytokinetics, Inc. | Polimorfy (r)-n-(5-(5-etylo-1,2,4-oksadiazol-3-ilo)-2,3-dihydro-1h-inden-1-ylo)-1-metylo-1h-pirazolo-4-karboksyamidu |
| KR20220082803A (ko) | 2019-07-17 | 2022-06-17 | 싸이토키네틱스, 인코포레이티드 | (r)-n-(5-(5-이소프로필-1,2,4-옥사디아졸-3-일)-2,3-디하이드로-1h-인덴-1-일)-2-메틸-2h-테트라졸-5-카르복사미드의 다형체들 |
| JP2023540485A (ja) | 2020-08-28 | 2023-09-25 | マイオカーディア，インク | ミオシンモジュレーターによる治療方法 |
| AU2022229390A1 (en) | 2021-03-04 | 2023-09-21 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| HRP20250174T1 (hr) | 2021-07-16 | 2025-04-11 | Cytokinetics, Inc. | Režimi za doziranje aficamtena za liječenje opstruktivne hipertrofične kardiomiopatije |
| JP2024530111A (ja) | 2021-08-03 | 2024-08-16 | サイトキネティックス， インコーポレイテッド | アフィカムテンを調製するための工程 |
| CA3249509A1 (en) | 2022-04-26 | 2023-11-02 | MyoKardia, Inc. | METHOD OF ADMINISTRATION OF MYOSIN INHIBITORS |
-
2019
- 2019-01-18 BR BR112020014428-2A patent/BR112020014428A2/pt active Search and Examination
- 2019-01-18 WO PCT/US2019/014344 patent/WO2019144041A1/en not_active Ceased
- 2019-01-18 CN CN202311746636.6A patent/CN117924208A/zh active Pending
- 2019-01-18 LT LTEPPCT/US2019/014344T patent/LT3740481T/lt unknown
- 2019-01-18 ES ES19703917T patent/ES2986630T3/es active Active
- 2019-01-18 MX MX2020007532A patent/MX2020007532A/es unknown
- 2019-01-18 MY MYPI2020003691A patent/MY203855A/en unknown
- 2019-01-18 PT PT197039175T patent/PT3740481T/pt unknown
- 2019-01-18 SI SI201930788T patent/SI3740481T1/sl unknown
- 2019-01-18 EP EP19703917.5A patent/EP3740481B9/en active Active
- 2019-01-18 SG SG11202006296YA patent/SG11202006296YA/en unknown
- 2019-01-18 US US16/252,483 patent/US10836755B2/en active Active
- 2019-01-18 CN CN202311746655.9A patent/CN117964573A/zh active Pending
- 2019-01-18 FI FIEP19703917.5T patent/FI3740481T3/fi active
- 2019-01-18 HR HRP20241014TT patent/HRP20241014T2/hr unknown
- 2019-01-18 TW TW113106914A patent/TWI898447B/zh active
- 2019-01-18 DK DK19703917.5T patent/DK3740481T5/da active
- 2019-01-18 HU HUE19703917A patent/HUE067913T2/hu unknown
- 2019-01-18 EP EP24179234.0A patent/EP4491622A3/en active Pending
- 2019-01-18 UY UY38057A patent/UY38057A/es active IP Right Grant
- 2019-01-18 AU AU2019208331A patent/AU2019208331C1/en active Active
- 2019-01-18 CA CA3252332A patent/CA3252332A1/en active Pending
- 2019-01-18 TW TW108101933A patent/TWI835770B/zh active
- 2019-01-18 MA MA51620A patent/MA51620B1/fr unknown
- 2019-01-18 RS RS20241047A patent/RS66042B9/sr unknown
- 2019-01-18 NZ NZ765795A patent/NZ765795A/en unknown
- 2019-01-18 SM SM20240329T patent/SMT202400329T1/it unknown
- 2019-01-18 KR KR1020207023807A patent/KR102797441B1/ko active Active
- 2019-01-18 PL PL19703917.5T patent/PL3740481T3/pl unknown
- 2019-01-18 CN CN201980009128.5A patent/CN111757875B/zh active Active
- 2019-01-18 MD MDE20201196T patent/MD3740481T3/ro unknown
- 2019-01-18 JP JP2020539814A patent/JP7401439B2/ja active Active
-
2020
- 2020-07-14 MX MX2022014312A patent/MX2022014312A/es unknown
- 2020-07-14 CL CL2020001871A patent/CL2020001871A1/es unknown
- 2020-07-16 PH PH12020551090A patent/PH12020551090A1/en unknown
- 2020-07-16 IL IL276094A patent/IL276094B2/en unknown
- 2020-07-27 CO CONC2020/0009225A patent/CO2020009225A2/es unknown
- 2020-07-31 EC ECSENADI202044709A patent/ECSP20044709A/es unknown
- 2020-09-04 US US17/013,472 patent/US11472796B2/en active Active
-
2022
- 2022-04-28 CL CL2022001091A patent/CL2022001091A1/es unknown
- 2022-08-31 US US17/823,910 patent/US12065436B2/en active Active
-
2023
- 2023-09-26 JP JP2023163639A patent/JP2023169374A/ja not_active Withdrawn
-
2024
- 2024-07-02 US US18/762,390 patent/US20250059173A1/en active Pending
- 2024-07-15 AU AU2024204859A patent/AU2024204859A1/en active Pending
-
2025
- 2025-04-10 JP JP2025065043A patent/JP2025106500A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022014312A (es) | Inhibidores de sarcomero cardiaco. | |
| MX2022008066A (es) | Compuestos triciclicos sustituidos. | |
| ZA202409114B (en) | MODULATORS OF THR-ß AND METHODS OF USE THEREOF | |
| MX2025002170A (es) | Inhibidores de kras g12c | |
| MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| CR20200588A (es) | Compuestos novedosos | |
| MX2025000642A (es) | Compuestos macrociclicos para el tratamiento de cancer | |
| PH12022551014A1 (en) | Substituted tricyclic compounds | |
| CR20210602A (es) | Compuestos de pirrolidina | |
| MX2025011447A (es) | Inhibidores de kras | |
| MX2023010125A (es) | Inhibidores del sarcomero cardiaco. | |
| PH12021551257A1 (en) | Cyclic pantetheine derivatives and uses thereof | |
| MY195576A (en) | Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof | |
| MX2024002409A (es) | Terapias contra el cancer. | |
| CR20220538A (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
| MX2024000028A (es) | Piridin-1,5-dionas espirocíclicas que exhiben inhibición de la proteína cinasa activada por mitógenos (mnk) y su método de uso. | |
| NZ790364A (en) | Compounds and compositions for use in treating skin disorders | |
| AR123049A1 (es) | Compuestos terapéuticos y modos de uso | |
| MX384745B (es) | Proceso para la preparación de compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidina-2,7-diona 3-sustituidos. | |
| CR20220231A (es) | Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria | |
| GEAP202516802A (en) | Protac chimeric compound, preparation method thereof and use thereof | |
| MX2024010431A (es) | Compuesto como inhibidor de fak y uso del mismo. | |
| PH12022552065A1 (en) | Agents for use in the treatment of tissue damage 2 | |
| EA202091733A1 (ru) | Аналоги дигидробензофурана и индена в качестве ингибиторов саркомера сердца |